Xinzhi Peng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2124892/publications.pdf

Version: 2024-02-01

1307594 1588992 9 163 7 8 citations g-index h-index papers 9 9 9 176 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 474-490.	3.6	11
2	Circular RNA_0057209 Acts as ceRNA to Inhibit Thyroid Cancer Progression by Promoting the STK4-Mediated Hippo Pathway via Sponging MicroRNA-183. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-25.	4.0	9
3	METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death and Disease, 2022, 13, 358.	6.3	31
4	Long nonâ€coding RNA TNRC6Câ€AS1 promotes methylation of STK4 to inhibit thyroid carcinoma cell apoptosis and autophagy via Hippo signalling pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 304-316.	3.6	24
5	Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1 $\hat{l}\pm$ and microRNA-146a. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2237-2251.	3.6	8
6	<p>Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis</p> . Cancer Management and Research, 2019, Volume 11, 8557-8569.	1.9	21
7	Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma. Oncology Reports, 2018, 41, 1253-1263.	2.6	0
8	CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomarkers, 2017, 18, 273-284.	1.7	23
9	Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma. International Journal of Oncology, 2017, 51, 1209-1218.	3.3	36